Covid-19 Long Immunité IMagerie (CLIIM)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Nice

About this trial

Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Case definition in line with WHO Delphi process

Disqualifiers

History of chronic fatigue syndrome diagnosed before or after Covid.

History of progressive psychiatric pathology.

History of acute Covid requiring admission to intensive care and mechanical ventilation.

No social security affiliation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Brain MRI

    Procedure/Surgery

    non injected brain MRI

  • Specific blood samples

    Biological/Vaccine

    blood samples to find immunological and inflammatory markers

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Covid-long (CL+)Other 2 interventions
Group B: Acute Covid (CL-)Other 2 interventions

Trial outcomes

Primary outcomes

1

Predictive model of Covid-long

Build and validate a multivariate predictive model of Covid-long considering immunological, inflammatory and brain imaging markers.

Time frame
24 months

Secondary outcomes

1

Evolution of these markers over time

Comparison of data over time between cohorts (CL+ vs. CL-)

Time frame
24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.